Literature DB >> 26288178

Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system.

Kristina Goetze1, Christian G Fabian1, Andrea Siebers1, Livia Binz1, Daniel Faber1, Stefano Indraccolo2, Giorgia Nardo2, Ulrike G A Sattler1, Wolfgang Mueller-Klieser3.   

Abstract

BACKGROUND: Malignant transformation of cells is often accompanied by up-regulation of glycolysis-related enzymes and transporters, as well as a distortion of mitochondrial respiration. As a consequence, most malignant tumors utilize high amounts of glucose and produce and accumulate high concentrations of lactate, even in the presence of oxygen. This phenomenon has been termed 'Warburg Effect'. Here, we aimed at resolving the interrelation between tumor metabolism, reactive oxygen species, double strand DNA breaks and radio-resistance in ovarian cancer-derived cells.
METHODS: As a model system two ovarian cancer-derived cell lines, OC316 and IGROV-1, and its corresponding xenografts were used. First, the metabolic properties of the xenografts were tested to ensure that initial in vitro data might later be transferred to in vivo data. In parallel, three inhibitors of tumor cell metabolism, 2-deoxy-D-glucose, an inhibitor of glycolysis, oxamate, a pyruvate analogue and inhibitor of lactate dehydrogenase, and rotenone, a specific inhibitor of mitochondrial electron complex I, were tested for their effect on the metabolism and radio-sensitivity of the respective ovarian cancer-derived cell lines.
RESULTS: We found that all three inhibitors tested led to significant changes in the tumor cell energy metabolism at non-cytotoxic concentrations. Furthermore, we found that inhibition of tumor glycolysis by 2-deoxy-D-glucose in combination with rotenone decreased the radio-resistance at a clinically relevant radiation dose. This apparent radio-sensitizing effect appears to be based on an increased level of double strand DNA breaks 1 h and 24 h after gamma irradiation. Both cancer-derived cell lines maintained their metabolic properties, as well as their protein expression profiles and levels of reactive oxygen species in xenografts, thus providing a suitable model system for further in vivo investigations.
CONCLUSION: A combination of metabolic inhibitors and reactive oxygen species-generating therapies, such as irradiation, may effectively enhance the therapeutic response in particularly metabolically highly active (ovarian) tumors.

Entities:  

Keywords:  Metabolic inhibitors; Ovarian cancer; Radiation therapy; Tumor metabolism; imBI

Mesh:

Substances:

Year:  2015        PMID: 26288178     DOI: 10.1007/s13402-015-0237-5

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  28 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas.

Authors:  A Alama; F Barbieri; A Favre; M Cagnoli; E Noviello; F Pedullà; M Viale; G Foglia; N Ragni
Journal:  Gynecol Oncol       Date:  1996-07       Impact factor: 5.482

3.  Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism.

Authors:  Yuhua Zhao; Hao Liu; Zixing Liu; Yan Ding; Susan P Ledoux; Glenn L Wilson; Richard Voellmy; Yifeng Lin; Wensheng Lin; Rita Nahta; Bolin Liu; Oystein Fodstad; Jieqing Chen; Yun Wu; Janet E Price; Ming Tan
Journal:  Cancer Res       Date:  2011-04-15       Impact factor: 12.701

4.  Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts.

Authors:  Christian Fabian; Lisa Koetz; Elena Favaro; Stefano Indraccolo; Wolfgang Mueller-Klieser; Ulrike G A Sattler
Journal:  FEBS J       Date:  2012-02-06       Impact factor: 5.542

Review 5.  The Warburg effect and mitochondrial stability in cancer cells.

Authors:  Vladimir Gogvadze; Boris Zhivotovsky; Sten Orrenius
Journal:  Mol Aspects Med       Date:  2009-12-06

Review 6.  The Warburg effect in 2012.

Authors:  Jean-Pierre Bayley; Peter Devilee
Journal:  Curr Opin Oncol       Date:  2012-01       Impact factor: 3.645

Review 7.  Otto Warburg's contributions to current concepts of cancer metabolism.

Authors:  Willem H Koppenol; Patricia L Bounds; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2011-04-14       Impact factor: 60.716

8.  SLUG silencing increases radiosensitivity of melanoma cells in vitro.

Authors:  Chiara Arienti; Anna Tesei; Silvia Carloni; Paola Ulivi; Antonino Romeo; Giulia Ghigi; Enrico Menghi; Anna Sarnelli; Elisabetta Parisi; Rosella Silvestrini; Wainer Zoli
Journal:  Cell Oncol (Dordr)       Date:  2012-12-19       Impact factor: 6.730

9.  Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death.

Authors:  Elena Favaro; Giorgia Nardo; Luca Persano; Massimo Masiero; Lidia Moserle; Rita Zamarchi; Elisabetta Rossi; Giovanni Esposito; Mario Plebani; Ulrike Sattler; Thomas Mann; Wolfgang Mueller-Klieser; Vincenzo Ciminale; Alberto Amadori; Stefano Indraccolo
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

Review 10.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nat Med       Date:  2013-10-07       Impact factor: 53.440

View more
  8 in total

1.  High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells.

Authors:  Luis Antonio Flores-López; María Guadalupe Martínez-Hernández; Rubí Viedma-Rodríguez; Margarita Díaz-Flores; Luis Arturo Baiza-Gutman
Journal:  Cell Oncol (Dordr)       Date:  2016-04-22       Impact factor: 6.730

2.  Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.

Authors:  Matteo Giulietti; Giulia Occhipinti; Giovanni Principato; Francesco Piva
Journal:  Cell Oncol (Dordr)       Date:  2016-05-30       Impact factor: 6.730

3.  Inactivation of the LKB1-AMPK signaling pathway does not contribute to salivary gland tumor development - a short report.

Authors:  Natascha Cidlinsky; Giada Dogliotti; Tobias Pukrop; Rudolf Jung; Florian Weber; Michael P Krahn
Journal:  Cell Oncol (Dordr)       Date:  2016-08-01       Impact factor: 6.730

4.  Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.

Authors:  Yan Gao; Jacson Shen; Edwin Choy; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Cell Oncol (Dordr)       Date:  2017-02-27       Impact factor: 6.730

5.  6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.

Authors:  Hailing Yang; Zhang Shu; Yongying Jiang; Weiqun Mao; Lan Pang; Abena Redwood; Sabrina L Jeter-Jones; Nicholas B Jennings; Argentina Ornelas; Jinhua Zhou; Cristian Rodriguez-Aguayo; Geoffrey Bartholomeusz; LaKesla R Iles; Niki M Zacharias; Steven W Millward; Gabriel Lopez-Berestein; Xiao-Feng Le; Ahmed A Ahmed; Helen Piwnica-Worms; Anil K Sood; Robert C Bast; Zhen Lu
Journal:  Clin Cancer Res       Date:  2019-08-07       Impact factor: 12.531

6.  Feasibility of induced metabolic bioluminescence imaging in advanced ovarian cancer patients: first results of a pilot study.

Authors:  Marco Johannes Battista; Kristina Goetze; Marcus Schmidt; Cristina Cotarelo; Veronika Weyer-Elberich; Annette Hasenburg; Wolfgang Mueller-Klieser; Stefan Walenta
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-24       Impact factor: 4.553

Review 7.  Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.

Authors:  Antonieta Chavez-Gonzalez; Babak Bakhshinejad; Katayoon Pakravan; Monica L Guzman; Sadegh Babashah
Journal:  Cell Oncol (Dordr)       Date:  2016-09-27       Impact factor: 6.730

Review 8.  Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.

Authors:  Su Yeon Lee; Eui Kyong Jeong; Min Kyung Ju; Hyun Min Jeon; Min Young Kim; Cho Hee Kim; Hye Gyeong Park; Song Iy Han; Ho Sung Kang
Journal:  Mol Cancer       Date:  2017-01-30       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.